Cybin (CYBN) Competitors $7.38 -1.62 (-18.00%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$7.84 +0.47 (+6.30%) As of 05:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. ANAB, URGN, NUVB, IOVA, ABUS, DAWN, GHRS, SION, STOK, and CDXCShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include AnaptysBio (ANAB), Urogen Pharma (URGN), Nuvation Bio (NUVB), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), and ChromaDex (CDXC). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Its Competitors AnaptysBio Urogen Pharma Nuvation Bio Iovance Biotherapeutics Arbutus Biopharma Day One Biopharmaceuticals GH Research Sionna Therapeutics Stoke Therapeutics ChromaDex Cybin (NYSE:CYBN) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment. Which has stronger earnings & valuation, CYBN or ANAB? Cybin has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.38-1.68AnaptysBio$91.28M7.69-$145.23M-$4.85-4.92 Is CYBN or ANAB more profitable? Cybin has a net margin of 0.00% compared to AnaptysBio's net margin of -125.70%. Cybin's return on equity of -37.58% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% AnaptysBio -125.70%-282.47%-30.79% Does the media prefer CYBN or ANAB? In the previous week, Cybin had 5 more articles in the media than AnaptysBio. MarketBeat recorded 7 mentions for Cybin and 2 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 1.69 beat Cybin's score of 0.28 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, CYBN or ANAB? Cybin has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Do insiders and institutionals have more ownership in CYBN or ANAB? 17.9% of Cybin shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 33.5% of AnaptysBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate CYBN or ANAB? Cybin presently has a consensus price target of $86.00, indicating a potential upside of 1,065.31%. AnaptysBio has a consensus price target of $42.38, indicating a potential upside of 77.45%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 SummaryCybin beats AnaptysBio on 10 of the 15 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$169.92M$782.11M$5.54B$20.53BDividend YieldN/A4.84%5.39%3.77%P/E Ratio-1.681.0926.1927.85Price / SalesN/A219.25414.0437.49Price / CashN/A23.4436.1321.91Price / Book0.685.998.024.55Net Income-$57.88M-$27.64M$3.15B$984.95M7 Day Performance-13.99%-0.07%1.48%2.31%1 Month Performance-11.30%6.49%3.67%4.85%1 Year PerformanceN/A8.20%34.68%13.81% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.641 of 5 stars$7.38-18.0%$86.00+1,065.3%N/A$169.92MN/A-1.6850High Trading VolumeANABAnaptysBio2.1207 of 5 stars$22.82-1.5%$42.38+85.7%-0.3%$680.75M$91.28M-4.71100Positive NewsURGNUrogen Pharma4.5592 of 5 stars$14.30-2.4%$32.86+129.8%-14.4%$675.47M$90.40M-4.50200High Trading VolumeNUVBNuvation Bio3.4885 of 5 stars$2.02+2.3%$7.17+255.7%-31.0%$670.32M$7.87M-0.8660High Trading VolumeIOVAIovance Biotherapeutics4.7038 of 5 stars$1.85-6.6%$12.22+560.7%-77.4%$661.19M$164.07M-1.49500Gap DownABUSArbutus Biopharma1.9394 of 5 stars$3.41-0.6%$5.50+61.3%+1.9%$656.94M$6.17M-8.3290DAWNDay One Biopharmaceuticals2.1516 of 5 stars$6.48+2.5%$30.57+371.8%-50.0%$640.61M$131.16M-9.1360Upcoming EarningsGHRSGH Research2.0993 of 5 stars$11.68-5.1%$32.00+174.0%+26.2%$640.47MN/A-14.7810SIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$639.36MN/A0.0035News CoveragePositive NewsInsider TradeGap UpSTOKStoke Therapeutics4.0302 of 5 stars$11.59+0.1%$23.20+100.2%-10.0%$632.23M$36.56M14.67100Analyst ForecastCDXCChromaDex3.1963 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120 Related Companies and Tools Related Companies ANAB Competitors URGN Competitors NUVB Competitors IOVA Competitors ABUS Competitors DAWN Competitors GHRS Competitors SION Competitors STOK Competitors CDXC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYBN Stock Alerts